JP2024086827A5 - - Google Patents

Download PDF

Info

Publication number
JP2024086827A5
JP2024086827A5 JP2024062460A JP2024062460A JP2024086827A5 JP 2024086827 A5 JP2024086827 A5 JP 2024086827A5 JP 2024062460 A JP2024062460 A JP 2024062460A JP 2024062460 A JP2024062460 A JP 2024062460A JP 2024086827 A5 JP2024086827 A5 JP 2024086827A5
Authority
JP
Japan
Prior art keywords
uapc
cell
composition
cells
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024062460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024086827A (ja
JP7837068B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2019/018989 external-priority patent/WO2019165097A1/en
Application filed filed Critical
Publication of JP2024086827A publication Critical patent/JP2024086827A/ja
Publication of JP2024086827A5 publication Critical patent/JP2024086827A5/ja
Application granted granted Critical
Publication of JP7837068B2 publication Critical patent/JP7837068B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024062460A 2018-02-21 2024-04-09 ユニバーサル抗原提示細胞およびその使用 Active JP7837068B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862633587P 2018-02-21 2018-02-21
US62/633,587 2018-02-21
PCT/US2019/018989 WO2019165097A1 (en) 2018-02-21 2019-02-21 Universal antigen presenting cells and uses thereof
JP2020544206A JP7591405B2 (ja) 2018-02-21 2019-02-21 ユニバーサル抗原提示細胞およびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020544206A Division JP7591405B2 (ja) 2018-02-21 2019-02-21 ユニバーサル抗原提示細胞およびその使用

Publications (3)

Publication Number Publication Date
JP2024086827A JP2024086827A (ja) 2024-06-28
JP2024086827A5 true JP2024086827A5 (https=) 2025-03-18
JP7837068B2 JP7837068B2 (ja) 2026-03-30

Family

ID=67686940

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544206A Active JP7591405B2 (ja) 2018-02-21 2019-02-21 ユニバーサル抗原提示細胞およびその使用
JP2024062460A Active JP7837068B2 (ja) 2018-02-21 2024-04-09 ユニバーサル抗原提示細胞およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020544206A Active JP7591405B2 (ja) 2018-02-21 2019-02-21 ユニバーサル抗原提示細胞およびその使用

Country Status (18)

Country Link
US (1) US20200390815A1 (https=)
EP (1) EP3755347B1 (https=)
JP (2) JP7591405B2 (https=)
KR (1) KR20200123459A (https=)
CN (1) CN112292137A (https=)
AU (1) AU2019226021B2 (https=)
BR (1) BR112020016876A2 (https=)
CA (1) CA3091671A1 (https=)
DK (1) DK3755347T3 (https=)
ES (1) ES3035716T3 (https=)
FI (1) FI3755347T3 (https=)
MX (1) MX2020008801A (https=)
MY (1) MY210248A (https=)
PL (1) PL3755347T3 (https=)
PT (1) PT3755347T (https=)
SG (1) SG11202008008UA (https=)
TW (1) TWI899050B (https=)
WO (1) WO2019165097A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
MX2021006393A (es) * 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
MX2021011816A (es) * 2019-03-29 2021-10-22 Univ Texas Metodos para produccion de celulas car-nk y uso de las mismas.
US20220340927A1 (en) * 2019-09-01 2022-10-27 Exuma Biotech Corp. Methods and compositions for the modification and delivery of lymphocytes
CN115243713A (zh) * 2020-03-05 2022-10-25 埃克苏马生物技术公司 用于递送修饰的淋巴细胞聚集体的方法和组合物
TW202300520A (zh) * 2021-05-19 2023-01-01 大陸商上海詩健生物科技有限公司 特異性識別baff-r的嵌合抗原受體分子及其應用
CN113832190A (zh) * 2021-09-24 2021-12-24 中海峡(福建)细胞生物科技有限公司 一种利用基因工程修饰的滋养细胞的制备方法及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
US5939281A (en) 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
JP2002521489A (ja) 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション CpGオリゴヌクレオチドの立体異性体および関連する方法
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
EP1673389A2 (en) 2003-10-10 2006-06-28 Xencor Inc. Novel variants of cd40l protein
WO2005118788A2 (en) * 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CA2605631A1 (en) 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
US9121008B2 (en) * 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
US10611818B2 (en) * 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2011030851A1 (ja) * 2009-09-11 2011-03-17 タカラバイオ株式会社 ナチュラルキラー細胞の製造方法
WO2013163171A1 (en) 2012-04-24 2013-10-31 Kaufman Dan S Method for developing natural killer cells from stem cells
LT3578201T (lt) * 2012-06-28 2023-05-25 University Of Central Florida Research Foundation Incorporated Nk ląstelių metodai ir kompozicijos
EP3114215B1 (en) * 2014-03-07 2021-04-14 Emercell SAS Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease
WO2015154012A1 (en) * 2014-04-03 2015-10-08 Memorial Sloan-Kettering Cancer Center Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
HK1245080A1 (zh) 2014-10-27 2018-08-24 University Of Central Florida Research Foundation, Inc. 自然杀伤细胞的方法和组合物
EP3212774A4 (en) * 2014-10-31 2018-04-11 Baylor College of Medicine Survivin specific t-cell receptor targeting tumor but not t cells
US11154572B2 (en) * 2015-06-05 2021-10-26 Board Of Regents, The University Of Texas System Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
CN109789092A (zh) * 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
JP7086928B2 (ja) * 2016-07-25 2022-06-20 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変されたナチュラルキラー細胞を生成する方法および使用方法
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same
MX2021006393A (es) * 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.

Similar Documents

Publication Publication Date Title
JP2024086827A5 (https=)
Kagoya et al. Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy
Lee Cellular therapy: Adoptive immunotherapy with expanded natural killer cells
Stroncek et al. New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
TWI836160B (zh) 製備用於t細胞治療之t細胞的方法
JP2024150721A (ja) B細胞悪性腫瘍及び他のがんの治療に有用な自己t細胞を産生する方法、並びにその組成物
Alvarez-Fernández et al. A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy
Ye et al. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes
Shimasaki et al. Expanded and armed natural killer cells for cancer treatment
JP2025031794A5 (https=)
Delalat et al. 3D printed lattices as an activation and expansion platform for T cell therapy
JP2018524987A5 (https=)
JP2022520871A5 (https=)
Shook et al. Natural killer cell engineering for cellular therapy of cancer
JP2022542321A5 (https=)
CN1541113A (zh) 利用激活的t细胞使抗原提呈细胞成熟
JP2021513860A5 (https=)
FI3755347T3 (fi) Universaaleja antigeeniä esitteleviä soluja ja niiden käyttöjä
MX2023008162A (es) Composiciones y metodos para la expansion de celulas t y linfocitos infiltrantes del tumor.
Wang et al. Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context
Jedema et al. Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-γ secretion assay
DiGiusto et al. Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials
EP4079375A1 (en) Method for producing t cells having cell surface markers for cd45ra+ and ccr7+
Dwarshuis et al. Functionalized microcarriers improve T cell manufacturing by facilitating migratory memory T cell production and increasing CD4/CD8 ratio
Sun et al. Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional